Tocilizumab for Renal Graft Inflammation

ClinicalTrials.gov ID: NCT02108600

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02108600. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of the Efficacy and Safety of Tocilizumab for Treatment of Inflammation in the Renal Allograft

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Randomized open label clinical trial in which 48 renal transplant recipients with inflammation in the 6 month allograft biopsy will either continue usual immunosuppression or receive monthly Actemra (Tocilizumab) infusions for 6 months in addition to usual immunosuppression.

Study identification

NCT ID: NCT02108600
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Flavio Vincenti; Other
Enrollment: 33 participants

Conditions and interventions

Conditions

Late Complication From Kidney Transplant

Interventions

Tocilizumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2014 (Actual)
Primary completion: Dec 16, 2018 (Actual)
Completion: Dec 16, 2018 (Actual)
Last update posted: Mar 9, 2021

2014 – 2018

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
University of California, San Francisco	San Francisco	California	94143	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02108600, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 9, 2021 · Synced Nov 12, 2026